Market By Product, Application, Technology, End-user And Geography | Forecast 2019-2028
As per an analysis by Triton Market Research, the European molecular point of care diagnostics market is likely to surge with a CAGR of 14.37% during the forecasted period 2019-2028.
We provide additional customization based on your specific requirements. Request For Customization
The countries evaluated in the Europe molecular point of care diagnostics market are:
•          Italy
•          The United Kingdom
•          Germany
•          Russia
•          France
•          Spain Â
•          Rest of Europe
In the UK, the evaluation process of molecular point of care diagnostics is integrated with technology appraisal for the relative-target drug, unlike other countries. The MHRA (Medicines & Healthcare products Regulatory Agency) has established an assessment program where many tests from the particular biomarker are accessible. Also, compulsory funding for the pharmaceuticals recommended by NICE (National Institute for Health and Care Excellence) has fuelled the investments of the molecular point of care diagnostics.
However, even if the molecular diagnostics-associated drug is not considered cost-effective, these products are likely to be eligible for temporary funding. Hence, pharmaceutical companies will temporarily pay for some molecular diagnostics tests owing to uncertainty about NHS funding. The availability of reimbursement and temporary funding is anticipated to positively affect the molecular point of care diagnostics market in the United Kingdom.
In addition, various initiatives launched by the UK government are also aiding the further growth of the molecular diagnostics point of care, especially for influenza and respiratory disorders. It is reported that based on the guidance launched, point of care testing platforms must be linked to the LIMS (laboratory information management system) to ensure proper data quality and governance. Also, companies like QuantuMDx Group Ltd are trying to revolutionize the molecular diagnostics point of care market in the UK through their advanced technological platforms. These factors are likely to aid the regional market growth.
BioMerieux SA designs is a company that is engaged in the development, manufacturing and commercialization of in-vitro diagnostic products. The company basically offers its products to the infectious disease diagnosis market. Concerning the molecular diagnostics point of care market, the company produces PCR-based molecular diagnostic instruments & kits which are used for the diagnosis of infectious diseases. The company also uses advanced technologies like nucleic acid sequence-based amplification in the diagnosis process of infectious diseases. The company has its headquarters in Marcy l'Etoile, France.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  INCREASED GERIATRIC POPULATION REQUIRES MORE DIAGNOSTIC SERVICES
2.2.2.  HYBRIDIZATION OF AVAILABLE TECHNOLOGIES IS A PROMISING TREND
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1.  THREAT OF NEW ENTRANTS
2.3.2.  THREAT OF SUBSTITUTE
2.3.3.  BARGAINING POWER OF SUPPLIERS
2.3.4.  BARGAINING POWER OF BUYERS
2.3.5.  THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. REGULATORY FRAMEWORK
2.6.1.  EUROPE
2.7. MARKET DRIVERS
2.7.1.  DEMAND FOR DIAGNOSING PRESENCE OF SARS COV-2
2.7.2.  INCREASING DEMAND FOR NON-INVASIVE DIAGNOSIS
2.7.3.  RISE IN THE NUMBER OF DISEASES
2.8. MARKET RESTRAINTS
2.8.1.  HIGH CAPITAL REQUIREMENT
2.9. MARKET OPPORTUNITIES
2.9.1.  SPENDING ON RESEARCH & DEVELOPMENT
2.9.2.  INNOVATIONS IN THE MARKET
2.10. MARKET CHALLENGES
2.10.1. LACK OF HIGH COMPLEXITY TESTING CENTERS
3. EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK – BY PRODUCT
3.1. ASSAYS
3.2. INSTRUMENTS
3.3. SOFTWARE
4. EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY APPLICATION
4.1. INFECTIOUS DISEASE
4.1.1.  RESPIRATORY
4.1.2.  HOSPITAL-ACQUIRED INFECTIONS
4.1.3.  SEXUALLY-TRANSMITED INFECTIONS
4.1.4.  GASTROINTESTINAL INFECTIONS
4.2. ONCOLOGY
4.3. PRENATAL
4.4. OTHERS
5. EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY TECHNOLOGY
5.1. POLYMERASE CHAIN REACTION
5.1.1.  REAL-TIME PCR (Q-PCR)
5.1.2.  DIGITAL PCR (D-PCR)
5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
5.3. OTHER
6. EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY END-USER
6.1. HOSPITAL
6.2. CLINICS
6.3. DIAGNOSTIC CENTERS
6.4. OTHERS
7. EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. UNITED KINGDOM
7.2. GERMANY
7.3. FRANCE
7.4. SPAIN
7.5. ITALY
7.6. RUSSIA
7.7. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT
8.2. ABACUS DIAGNOSTICA
8.3. BIOMERIEUX SA
8.4. BIOCARTIS
8.5. DANAHER
8.6. DIASORIN SPA
8.7. BIO-RAD LABORATORIES INC
8.8. F HOFFMANN-LA ROCHE LTD
8.9. LUMINEX CORPORATION
8.10. HOLOGIC INC
8.11. MESA BIOTECH
8.12. SPARTAN BIOSCIENCES INC
8.13. QUANTUMDX GROUP LTD
8.14. QUIDEL CORPORATION
8.15. QIAGEN
9. METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY
TABLE 1: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 5: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 6: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 7: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 8: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 9: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 10: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: COST COMPARISON BETWEEN LABORATORY, IMMUNOASSAY AND MOLECULAR POC DIAGNOSTIC TESTS
FIGURE 3: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)
FIGURE 4: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)
FIGURE 5: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)
FIGURE 6: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 7: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)
FIGURE 8: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL-ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 9: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY-TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 10: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTROINTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 11: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)
FIGURE 13: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
FIGURE 15: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL-TIME PCR (Q-PCR), 2019-2028 (IN $ MILLION)
FIGURE 16: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR (D-PCR), 2019-2028 (IN $ MILLION)
FIGURE 17: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 18: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)
FIGURE 19: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL, 2019-2028 (IN $ MILLION)
FIGURE 20: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 21: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTERS, 2019-2028 (IN $ MILLION)
FIGURE 22: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 23: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)
FIGURE 24: UNITED KINGDOM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: GERMANY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: FRANCE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: SPAIN MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: ITALY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: RUSSIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: REST OF EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)